2-Bromopalmitate Reduces Protein Deacylation by Inhibition of Acyl-Protein Thioesterase Enzymatic Activities

Maria P. Pedro1, Aldo A. Vilcaes1, Vanesa M. Tomatis2, Rafael G. Oliveira1, Guillermo A. Gomez3, Jose L. Daniotti1*

1 Centro de Investigaciones en Química Biológica de Córdoba, Departamento de Química Biológica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina, 2 Queensland Brain Institute, The University of Queensland, Queensland, Australia, 3 Division of Molecular Cell Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Brisbane, Queensland, Australia

Abstract

S-acylation, the covalent attachment of palmitate and other fatty acids on cysteine residues, is a reversible post-translational modification that exerts diverse effects on protein functions. S-acylation is catalyzed by protein acyltransferases (PATs), while deacylation requires acyl-protein thioesterases (APT), with numerous inhibitors for these enzymes having already been developed and characterized. Among these inhibitors, the palmitate analog 2-bromopalmitate (2-BP) is the most commonly used to inhibit palmitoylation in cells. Nevertheless, previous results from our laboratory have suggested that 2-BP could affect protein deacylation. Here, we further investigated in vivo and in vitro the effect of 2-BP on the acylation/deacylation protein machinery, with it being observed that 2-BP, in addition to inhibiting PAT activity in vivo, also perturbed the acylation cycle of GAP-43 at the level of depalmitoylation and consequently affected its kinetics of membrane association. Furthermore, 2-BP was able to inhibit in vitro the enzymatic activities of human APT1 and APT2, the only two thioesterases shown to mediate protein deacylation, through an uncompetitive mechanism of action. In fact, APT1 and APT2 hydrolyzed both the monomeric form as well as the micellar state of the substrate palmitoyl-CoA. On the basis of the obtained results, as APTs can mediate deacylation on membrane bound and unbound substrates, this suggests that the access of APTs to the membrane interface is not a necessary requisite for deacylation. Moreover, as the enzymatic activity of APTs was inhibited by 2-BP treatment, then the kinetics analysis of protein acylation using 2-BP should be carefully interpreted, as this drug also inhibits protein deacylation.

Introduction

Fatty-acylated peripheral proteins, such as members of the small G-protein Ras family, the neuronal proteins PSD-95 and growth-associated protein–43 (GAP-43) [1–5], are synthesized in the cytosol and post-translationally modified by different lipid moieties [6–8], with these modifications governing their membrane association and membrane subdomain segregation, as well as their trafficking, function and stability [9,10].

Despite the many post-translational lipid modifications of proteins that have been achieved, including isoprenylation and myristoylation, the addition of fatty acid to the sulfhydryl group of a cysteine to form a thioester bond (S-acylation, often referred as palmitoylation) is the only known readily reversible linkage that has a much shorter half-life than that of the protein itself [11–16]. Consequently, S-acylation can operate as a switch, regulating not only the protein-membrane binding affinity and segregation, but also modulating the proteins biological activities [17–19]. S-acylation is catalyzed by protein acyltransferases (PATs) whereas deacylation requires acyl-protein thioesterases (APTs).

PATs have been identified both in yeast and mammals [20,21] and have a 51-amino-acid domain containing a DHHC (aspartate-histidine-histidine-cysteine) motif and a high abundance of cysteine residues. Additionally, a novel and conserved 16-amino-acid motif present at the cytosolic C-terminus of PATs was recently identified to be required for protein acylation mediated by PAT [22]. The mammalian and yeast genomes encode up to 24 PATs and 7 PATS, respectively, which are integral membrane proteins predicted to contain 4 to 6 transmembrane domains. S-acylation has been reported to occur in several membrane compartments [1,23–25] with apparent substrate selectivity. However, S-acylation of semisynthetic substrates is detectable only in the Golgi complex with substrate specificity not being essential for the reacylation step [26,27].

The enzymes mediating deacylation have not been characterized as extensively as the PATs, and only two cytosolic APTs have been described to date: APT1 and APT2, which were originally
isolated as lysophospholipases and later demonstrated to be effective as protein thioesters [19,28–30]. Although APTs mediate fatty acid turnover on many cytoplasmic proteins, such as heterotrimeric G protein α subunits, endothelial nitric-oxide synthase, SNAP-23, GAP-43 and H-Ras, it has been demonstrated that APT1 and APT2 are more selective. For instance, caveolin and GAP-43 are not deacylated by APT1 [29,31], calcium-activated potassium channel is not deacylated by APT2 [32] and not all substrates are deacylated with the same efficiency [33].

The palmitate analog 2-BP is a electrophilic ζ-brominated fatty acid which has been widely used to inhibit the palmitoylation of several proteins, including the H-Ras, GAP-43 and Rho family kinases [5,36,40]. In fact, 2-BP acts as a general inhibitor of palmitate incorporation and does not appear to selectively inhibit the acylation of specific protein substrates. It was also found to inhibit fatty acid CoA ligase and other enzymes involved in lipid metabolism, thus affecting the levels of intracellular palmitoyl-CoA, a necessary donor substrate for S-acylation [41].

During the course of previous experiments carried out in our laboratory to investigate the mechanisms of GAP-43 membrane affinity, it was observed that PAT inhibition with 150 μM 2-BP completely eliminated acylation of newly synthesized GAP-43, and consequently its binding to the membranes. However, at steady-state conditions, 2-BP treatment did not modify the acylation state or membrane binding properties of GAP-43 [5], thereby strongly suggesting that membrane-associated GAP-43 was not being deacylated and that 2-BP not only inhibits PATs but also APT activity. Some subsequent experiments were therefore conducted at lower concentrations of 2-BP in order to inhibit the PATs and minimally affecting the deacylating enzyme activities [29].

Taking into consideration that 2-BP is widely used to inhibit protein palmitoylation and that it is sometimes referred to as a “specific” inhibitor of acylation, we considered it essential to investigate further the in vivo and in vitro effects of 2-BP on the acylation/deacylation protein machinery, by paying particular attention to the deacylation enzymatic process. Briefly, we observed that 2-BP in vivo, in addition to inhibiting PAT activity, also perturbed the acylation cycle of GAP-43 at the level of deacylation. Next, the study was extended to evaluate the ability of 2-BP to affect the enzymatic activities of recombinant human APT1 and APT2 in vitro. Interestingly, both thioesterases showed a significant profile of inhibition by 2-BP. On the basis of these results, we concluded that 2-BP treatment inhibits the APT1 and APT2 activities both in vitro and in vivo. This not only implies that the kinetics analysis of protein acylation using 2-BP should be carefully interpreted because this drug also inhibits protein deacylation, but also suggests that the 2-BP moiety can be used as a model for the rational design of new drugs that may be able to modify the oncogenic signaling of acylated proteins (i.e. N- and H-Ras), which may lead to the development of new therapies for cancer.

Results

2-BP Inhibits PAT Activity and hence the Membrane Association of a Single Acylated Protein

To investigate in vivo the effect of 2-BP on the acylation/deacylation protein machinery, we set up a direct method for acylation/deacylation readout using a monoacylated mutant of GAP-43, which requires a single acylation event for its membrane association. GAP-43 is a dually palmitoylated protein found in caveolae, which may lead to the development of new therapies for cancer.

Inhibition of Protein Deacylation by 2-BP

Having demonstrated that 2-BP inhibited PAT activity in vivo at a range of concentrations between 25 and 150 μM, we next investigated whether the ζ-brominated fatty acid could also perturb the deacylation kinetics of monoacylated GAP-43 at the same concentrations. Thus, CHO-K1 cells transiently coexpressing N13GAP-43(C3S) and GalNAc-T (TGN marker) were treated with 25, 50 and 150 μM 2-BP (2-BP) or dimethylsulfoxide (DMSO, Control) and the GAP-43 subcellular distribution was monitored at different times by live cell confocal fluorescent microscopy, with cycloheximide (CHX) and protein degradation inhibitors being incorporated to the culture medium 1 h before and during 2-BP treatment (Fig. 2A). In control cells, the amount of TGN-membrane association of GAP-43(C3S) did not significantly change over time, whereas in cells treated with 25 μM 2-BP, the TGN-associated fraction of GAP-43 significantly decreased over time with a half-life of 3.5±0.1 min (Fig. 2B, C and D; and movie S1). Interestingly, a significant reduction in the N13GAP-43(C3S) depalmitoylation rate was clearly observed at higher 2-BP concentrations (Fig. 2B). The calculated half-life of the TGN-associated fraction of GAP-43(C3S) in cells treated with 50 and 150 μM 2-BP was 3.4±0.3 and 8.8±0.2 min, respectively
However, the observed decrease of the TGN-membrane association of GAP-43(C3S) in 2-BP conditions was not attributable to TGN membrane redistribution since the TGN marker GalNAc-T was not affected under these experimental conditions (Fig. 2E) nor due to an increase in the TGN to plasma membrane vesicular transport of N13GAP-43(C3S), since all experiments were performed at 20°C, a condition which drastically decreases this process [5].

Finally, the effect of 2-BP on membrane association of wild-type diacylated GAP-43 was evaluated (Fig. 3). Interestingly, it was observed that in cells treated up to 6 h with 150 μM 2-BP the membrane association of GAP-43 did not significantly change compared to control conditions. In contrast, when cells were treated with 25 and 50 μM 2-BP there was a significant amount of soluble GAP-43 at 3 h, with this being more evident at 6 h. Taken together, these results indicate that 2-BP, in addition to its demonstrated inhibition of protein acylation, can also perturb the protein deacylation in vivo, probably by affecting the catalytic proprieties of thioesterases.

Enzymological Characterization and Effect of 2-BP on Human APT1 and APT2 Activities

Up to this point, our results indicate that 2-BP perturbs deacylation in living cells. Therefore, we investigated the effect of 2-BP on the activities of recombinant human APT1 and APT2, which are the only two bona fide thioesterases that have been shown to mediate deacylation [19,29]. First, both human thioesterases were expressed in *Escherichia coli*, purified to apparent homogeneity and biochemically characterized (Fig. 4). As observed in Figure 4A and B, both APT1 and APT2 migrated with an apparent molecular mass of 26 kDa, although at

(Fig. 2C and D; and movie S1). However, the observed decrease of the TGN-membrane association of GAP-43(C3S) in 2-BP conditions was not attributable to TGN membrane redistribution since the TGN marker GalNAc-T was not affected under these experimental conditions (Fig. 2E) nor due to an increase in the TGN to plasma membrane vesicular transport of N13GAP-43(C3S), since all experiments were performed at 20°C, a condition which drastically decreases this process [5].

Finally, the effect of 2-BP on membrane association of wild-type diacylated GAP-43 was evaluated (Fig. 3). Interestingly, it was observed that in cells treated up to 6 h with 150 μM 2-BP the membrane association of GAP-43 did not significantly change compared to control conditions. In contrast, when cells were treated with 25 and 50 μM 2-BP there was a significant amount of soluble GAP-43 at 3 h, with this being more evident at 6 h. Taken together, these results indicate that 2-BP, in addition to its demonstrated inhibition of protein acylation, can also perturb the protein deacylation in vivo, probably by affecting the catalytic proprieties of thioesterases.

Enzymological Characterization and Effect of 2-BP on Human APT1 and APT2 Activities

Up to this point, our results indicate that 2-BP perturbs deacylation in living cells. Therefore, we investigated the effect of 2-BP on the activities of recombinant human APT1 and APT2, which are the only two bona fide thioesterases that have been shown to mediate deacylation [19,29]. First, both human thioesterases were expressed in *Escherichia coli*, purified to apparent homogeneity and biochemically characterized (Fig. 4). As observed in Figure 4A and B, both APT1 and APT2 migrated with an apparent molecular mass of 26 kDa. Then, to test whether both recombinant proteins were enzymatically actives, we evaluated their ability to hydrolyze palmitoyl-CoA, which is a substrate widely used to measure thioesterases. It was observed using a dose-response curves that APT1 and APT2 hydrolyzed palmitoyl-CoA with Km values of 0.14 and 0.35 mM, respectively (Fig. 4C). Interestingly, both enzymes hydrolyzed the monomeric form as well as the micellar state of the substrate palmitoyl-CoA (CMC 100–180 μM), although at
higher concentrations of this substrate the deacylation mediated by APTs was inhibited (Fig. 5A and B). These results are of biological relevance, since both thioesterases are mainly expressed in the cytoplasm with a high hydrophilic character (Fig. 6) and might catalyze the hydrolysis of both soluble and membrane-bound substrates. Moreover, it also implies that the structure of the substrate, which depends on the membrane microenvironment, is important in determining the deacylation kinetics, which was also further investigated by Small-angle X-ray scattering (SAXS) analysis (Fig. 5C). As expected, no aggregation of palmitoyl-CoA was observed at 50 μM. However, micellar aggregation was evident at both 300 and 600 μM. Interestingly, at 1775 μM palmitoyl-CoA the SAXS curve changed its shape, indicating that a new kind of aggregate appeared that was compatible with globular micelles (for additional information and analysis see the legend of Fig. 5C). As this occurred in the range of substrate concentration at which the APT activity was lost (Fig. 5A and B), it probably indicates that changes in the structure of the lipid substrate severely affected the enzyme-substrate interaction. However, this
phenomenon was not observed when the zwitterionic detergent CHAPS was present in the reaction (Fig. 5A and B), which eventually led to the formation of mixed micelles [13].

After biochemical and enzymological characterization of recombinant human APT1 and APT2, we next evaluated the effect of 2-BP on their enzymatic activities. As shown in Figure 7, a drastic and significant reduction of APT1 activity was observed at 50 and 100 \( \mu \text{M} \) 2-BP, with the molecular mechanism of inhibition appearing to be of an uncompetitive type with the apparent \( V_{\text{max}} \) and \( K_{\text{m}} \) values reduced. Thus, according to this type of enzymatic inhibition, 2-BP would be expected to bind to the enzyme-substrate complex. In the case of APT2, there was a significant effect of 2-BP on its enzymatic activity, reaching 17% and 30% inhibition at 50 and 100 \( \mu \text{M} \) 2-BP, respectively.

Discussion

In the present study we have shown that in vivo treatment with 2-BP, in addition to inhibiting PAT activity, also perturbed the turnover of palmitate moieties on GAP-43 by inhibiting the acyl-protein thioesterases. In particular, it was observed that 2-BP strongly inhibited PAT activity over a range of concentrations from 25 \( \mu \text{M} \) to 150 \( \mu \text{M} \). In addition, the TGN-associated fraction of \( ^{3} \text{H}\)GAP-43(C3S), which is highly dependent on the acylation state of the protein, significantly decreased over the time of 2-BP treatment, revealing a half-life of membrane association which is directly proportional to the 2-BP concentration. A similar result was also observed for the diacylated wild-type GAP-43.

The electrophilic \( \alpha \)-brominated fatty acid 2-BP, which is highly reactive toward thiols, has been demonstrated to alkylate many membrane-bound proteins through non-specific and non-competitive mechanisms [41]. Although the precise way in which 2-BP exerts this effect is unknown, taking into account the hydrophobic nature of 2-BP, it seems likely that the brominated inhibitor inserts itself into the lipid bilayer and gains access to membrane-bound proteins. In the same way, the soluble proteins that interact with the interface may also be modified by 2-BP. Additionally, 2-BP might act indirectly by modifying the surrounding lipid environment, and hence affect the catalytic properties of integral membrane proteins, such as the PATs. It is also known that 2-BP is converted to 2-BP-CoA inside the cell, which is a non-
metabolizable molecule, and the binding of 2-BP to PATs could result in formation of an inhibitor:enzyme complex, thereby affecting the transfer of 2-BP to the acceptor protein. Importantly, 2-BP may also alter lipid metabolism in general, and protein acylation in particular, by reducing the level of intracellular palmitoyl-CoA, which is a necessary donor substrate for palmitoylation [34,35]. In consequence, evidences indicate that 2-BP exerts multiples, and probably cumulative, effects on the cellular metabolism.

The enzymological analysis performed in this work with recombinant human APTs clearly indicates the significant profile of inhibition of 2-BP. These assays permit us to speculate that the brominated fatty acid is probably perturbing the thioesterase activities through an uncompetitive mechanism resulting from a direct modification of the enzyme, possibly by alkylation.

Recently, it was reported that APT1 and APT2 undergo palmitoylation on cisteine-2 [42], which was suggested to facilitate the steady-state membrane localization and function of these thioesterases. Nevertheless, experimental evidence obtained in our laboratory by biochemical and cell biology assays in CHO-K1 cells has demonstrated that both enzymes are mainly cytosolic with a high hydrophilic character (Fig. 6). Consequently, it is highly probable that non-acylated APTs could transiently associate with the interface in order to exert their catalytic activities. In line with

Figure 5. Dose-response curve for APT activities following different concentrations of palmitoyl-CoA and the structural characterization of the substrate by SAXS analysis. The initial rate of palmitoyl-CoA hydrolase activity was measured with 0.5 μg of recombinant APT1 (A) or APT2 (B), both in control conditions (-CHAPS -Mg2+, left bars) or in the presence of 7.5 mM CHAPS and 2 mM MgCl2 (+CHAPS +Mg2+, right bars) at 150, 300, 600 and 1500 μM. Data show the initial rate of the reaction (V, μM/min) at different concentrations of palmitoyl-CoA (P-CoA), which are from representative experiments performed in triplicate. C) SAXS analysis. Palmitoyl-CoA was resuspended in buffer (50 mM Hepes, pH 8.0) at 50, 300, 600 and 1775 μM, and measurement were carried out as indicated in Materials and methods. The figure shows the SAXS raw data (after subtraction of the buffer background and the concentration normalization) for increasing concentrations of palmitoyl-CoA. As can be seen, no noticeable diffraction peak (due to any strong correlation) is observed in any of the curves. The curve for 50 μM palmitoyl-CoA does not display any obvious tendencies. The curves for 300 and 600 μM show increasing intensity at a very low angle, adopting similar slopes and absolute values. The curve at 1775 shows a different behavior with an increment at a low angle, which reached a plateau below 0.3 nm⁻¹ with a prominent bump centered at 1.6–1.7 nm⁻¹ (very common in bilayers and micelles). In agreement with the wedge-shaped molecular structure, this molecule did not display the global form factor of bilayers, but rather one of the micelles. This is evident from the non-quadratic decay of the intensity as a function of q. The saturation value at low q (Guiniers approximation) for the 1775 μM may indicate globular micelles. The clear differences present between the curves at 300–600 μM and the one at 1775 μM is probably due to the fact that the micelles have a different geometry, with the decay at low q values (q<0.5 nm⁻¹) having a finite slope closer to an inverse (first power) behavior, suggesting rod-like structures.

doi:10.1371/journal.pone.0075232.g005
this assumption, recombinant APT1 and APT2 (which are not acylated when expressed in bacteria) hydrolyze the substrate (palmitoyl-CoA) both in its monomeric form or micellar state. In contrast to what has been reported for certain enzymes with membrane-associated substrates (i.e., phospholipases and lipases) [43,44], we observed that the APTs do not display interfacial activation, as was previously observed for APT1 activity over lysophosphocholine [45]. However, various results do indicate that changes in the structure of the lipid substrate drastically affect the APTs-substrate interaction.

Using confocal and video fluorescence microscopy on living cells, we demonstrated that the kinetic of deacylation of the monoacylated N13GAP-43, even at the highest 2-BP concentration, was clearly much faster (minutes) than its wild-type diacylated counterpart (hours). A similar behavior has also been observed in two isoforms of Ras GTPases [11,15,46]. The half-life of palmitate on N-Ras (monoacylated) is 20 min and for H-Ras (diacylated) is 2.4 h, with a simple interpretation being that the double acylation is responsible for this longer half-life of palmitate and suggesting that monoacylated species are the preferred substrates for thioesterases. However, it should be mentioned that at steady-state conditions the monopalmitoylated fraction of GAP-43 represents 60% of the total GAP-43 protein [47], suggesting that the double palmitoylation is not an efficient mechanism of acylation in vivo. Consequently, we hypothesize that an important physiological role for APT could be in deacylating single acylated substrates, which should later be in condition to perform another cycle of acylation, or eventually, be sorted for degradation via the ubiquitin-proteasome system [29,48,49].

Summing up, our results indicate that 2-BP should be used carefully in the study of the role of PATs in the regulation of protein palmitoylation and function, thus avoiding an erroneous interpretation of kinetic analysis, due to this drug also inhibiting protein deacylation. Nevertheless, controlled experimental conditions using 2-BP could be beneficial in order to “freeze” the turnover of palmitate on palmitoylated proteins, which may be responsible for this longer half-life of palmitate and suggesting that monoacylated species are the preferred substrates for thioesterases. However, it should be mentioned that at steady-state conditions the monopalmoylated fraction of GAP-43 represents 60% of the total GAP-43 protein [47], suggesting that the double palmitoylation is not an efficient mechanism of acylation in vivo. Consequently, we hypothesize that an important physiological role for APT could be in deacylating single acylated substrates, which should later be in condition to perform another cycle of acylation, or eventually, be sorted for degradation via the ubiquitin-proteasome system [29,48,49].

Summing up, our results indicate that 2-BP should be used carefully in the study of the role of PATs in the regulation of protein palmitoylation and function, thus avoiding an erroneous interpretation of kinetic analysis, due to this drug also inhibiting protein deacylation. Nevertheless, controlled experimental conditions using 2-BP could be beneficial in order to “freeze” the turnover of palmitate on palmitoylated proteins, which may be responsible for this longer half-life of palmitate and suggesting that monoacylated species are the preferred substrates for thioesterases. However, it should be mentioned that at steady-state conditions the monopalmoylated fraction of GAP-43 represents 60% of the total GAP-43 protein [47], suggesting that the double palmitoylation is not an efficient mechanism of acylation in vivo. Consequently, we hypothesize that an important physiological role for APT could be in deacylating single acylated substrates, which should later be in condition to perform another cycle of acylation, or eventually, be sorted for degradation via the ubiquitin-proteasome system [29,48,49].
permit investigation into the importance of deacylation in the function of these proteins. One such example is Ras, whose deacylation is important for its correct subcellular distribution and function [25,50]. Our laboratory and other researchers have previously reported that APT1 and APT2 deacetylate H-Ras [13,29], and APTs have been used as molecular targets in the development of drugs to impair Ras signaling [51,52]. The finding reported in the present work that 2-BP has also the potential to inhibit APT1 and APT2 activity, implies that this moiety can be used as a model for the rational design of new drugs that may be able to modify the oncogenic signaling of Ras, and consequently, might lead to the development of new therapies for cancer.

Materials and Methods

Plasmids

The expression vectors pECFP-C1 (where ECFP is enhanced cyan fluorescent protein) and pEYFP-N1 (where EYFP is enhanced yellow fluorescent protein) were from Clontech (CA, USA). Expression plasmids for N13GAP-43(C3S)-YFP, N27GalNAc-T-CFP, APT1-Cherry and APT2-Cherry have been previously described [5,29,53].

Cell Culture and DNA Transfections

CHO-K1 cells (ATCC, Manassas, VA, USA) were maintained at 37°C, 5% CO₂ in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (ATB, 100 μg/ml penicillin and 100 μg/ml streptomycin). Cells grown on Petri dishes were used for both live cell imaging and western blot experiments. These cells were transfected with 0.8–1.5 μg/35 mm dish of the indicated plasmids using cationic liposomes (Lipofectamine, Invitrogen, CA, USA) or polyethyleneimine (PEI, Sigma-Aldrich, St. Louis, MO, USA). At 24 h after cell transfection, cells were processed for western blot experiments or plated onto Lab-Tek chambered coverglass (Thermo Scientific Nunc, IL, USA), incubated for 24 h, and then used in live cell imaging.

2-BP Treatment

A stock solution of 2-BP (0.42 M, Fluka, Sigma-Aldrich, St. Louis, MO, USA) was prepared in DMSO. To analyze the effect of 2-BP on the steady-state subcellular distribution of fluorescent proteins by live cell imaging experiments, CHO-K1 cells were treated with 60 μg/ml CHX (Sigma-Aldrich) and with inhibitors of protein degradation (60 μM cloroquine and 7.5 μM MG132). These inhibitors were added to the culture medium 36 h after transfection and plated onto Lab-Tek chambered coverglass (Thermo Scientific Nunc, IL, USA), incubated for 24 h, and then used in live cell imaging.

Expression and Purification of Recombinant APT1 and APT2

The APT1 and APT2 cDNA containing a His6 tag were obtained by RT-PCR using specific primers and RNA from the HeLa and CHO-K1 cells, respectively, and the amplified fragments were cloned into the BamHI/EcoRI sites of the bacterial expression vector pRSET-A (Invitrogen, CA, USA). Transformed Escherichia coli cells were grown at 37°C in Luria-Bertani (LB) medium containing 15 μg/ml ampicillin to an optical density of 0.6. Then, a soluble fraction was generated using a high pressure homogenizer (EmulsiFlex, Avestin, Inc., Ottawa, Canada), which was centrifugated at 10000 g for 15 min at 4°C. His6 APT1 and APT2 were then purified from the soluble lysate using a Ni²⁺-NTA column (GE Healthcare, Fairfield, VT, USA) according to the manufacturer’s instructions. The purified proteins were then desalted using HiTrap desalting columns (GE Healthcare, Fairfield, VT, USA).

Confocal Microscopy

Confocal images were collected using an Olympus FluoView FV1000 confocal microscope (Olympus Latin America, Miami, FL) equipped with a multi-line Argon laser (438, 488 and 514 nm) and two helium-neon lasers (543 nm and 633 nm, respectively). YFP was acquired by using laser excitation at 514 nm, a 458/514 nm excitation dichroic mirror, and a 530–560 nm band pass emission filter. Cherry protein was acquired with a laser excitation at 543 nm, a 488/543/633 nm excitation dichroic mirror, and a 560 nm long pass emission filter.

Live Cell Imaging for Deacylation Kinetic Measurements

For deacylation measurements, cells expressing N13GAP-43(C3S)-YFP were used. The live cell experiments were performed at 20°C on an Olympus FluoView FV1000 confocal microscope to minimize vesicular trafficking of GAP-43. After selection of the cells expressing the protein, images were acquired in the YFP channel for deacylation kinetic measurements using a 63×/1.42 NA PlanApo objective oil immersion (Olympus) with a 3× digital zoom. Image size was 512×512 pixels with a resolution of 165 μm/pixel, with the scan speed being 10 μs/pixel and the
pinhole adjusted to obtain an optical slice of 3 μm. Single 3D images were taken at a frequency of 1 min−1 for 30 minutes, with the acquisition conditions being optimized in order to acquire the Golgi compartment, to minimize bleaching during acquisition and to sample as quickly as possible the amount of N13 GAP-43(C3S) at the TGN [29]. All image analysis and the quantification method were carried out using ImageJ software as described previously [29].

Palmitoyl-CoA Hydrolase Assay
Palmitoyl-CoA hydrolase assays with purified APT1 or APT2 were performed following a protocol described by Duncan and Gilman [13] with some modifications.

Small-angle X-ray Scattering (SAXS) Measurements
SAXS was carried out at the SAXS2 beamline at the Brazilian Synchrotron Light Laboratory (LNLS) at Campinas, Brazil. Palmitoyl-CoA was resuspended in buffer (50 mM Hepes, pH 7.0) at 50, 300, 600 and 1775 μM, with the measurement conditions being 5 minutes of exposure, a sample-detector distance of 1 m, 1.5 Å irradiation, 30±1 °C. The buffer was measured and subtracted from the signals. Data was collected by a MARCCD and radially integrated by using FIT2D V 12.077 at ESRF. The SAXS curves were generated using the SASFIT free software, and the SAXS intensity was plotted as a function of the scattering angle.

Inhibition of Protein Deacylation by 2-BP

where λ is the X-ray wavelength and 2θ is the total scattering angle.

Supporting Information

Movie S1 Deacylation of N13 GAP-43(C3S) at different doses of 2-BP, CHO-K1 cells expressing N13 GAP-43(C3S)-YFP (pseudocolored green) were incubated in DMEM supplemented with CHX and protein degradation inhibitors at 20°C on the microscope stage, following the experimental procedure described in Fig. 2A. Cells were treated with 25, 50 or 150 μM 2-BP or DMSO (Control), and time series were acquired (1 frame/min) for the following 20 min, as indicated in Materials and methods. (MP4)

Acknowledgments

The authors thank the technical assistance of G. Schachner, S. Deza, C. Sampaio and C. Mas. R.G.O. thanks the Brazilian Synchrotron Light Laboratory (CNPEM/MCT) for x-ray beam time at SAXS2 beam line under project D11A - SAXS1 - 10716.

Author Contributions

Conceived and designed the experiments: MPP AAV VMT GAG JLD. Performed the experiments: MPP AAV VMT GAG JLD. Analyzed the data: MPP AAV VMT GAG JLD. Wrote the paper: MPP AAV VMT GAG JLD.

References

1. El-Husseini AE, Craven SE, Cherkovich DM, Firestein BL, Schnell E, et al. (2000) Dual palmitoylation of PSD-95 mediates its vesiculotubular sorting, postsynaptic targeting, and ion channel clustering. J Cell Biol 148: 159-172.
2. Huang K, El-Husseini A (2005) Modulation of neuronal protein trafficking and function by palmitoylation. Curr Opin Neurobiol 15: 527-535.
3. Marrari Y, Crouthamel M, Irannejad R, Wedegaertner PB (2007) Assembly and disassembly of caveolin-1. Biochemistry 46: 7665-7677.
4. Takai Y, Sasaki T, Matsumoto T (2001) Small GTP-binding proteins. Physiol Rev 81: 557-586.
5. Trenchi A, Gomez GA, Danioth JL (2009) Dual acylation is required for trafficking of growth-associated protein-43 (GAP-43) to the endosomal recycling compartment via an Arf6-associated endocytic vesicular pathway. Biochem J 421: 357-369.
6. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR (2012) Regulating the regulators: post-translational modification of RAS. Nat Rev Mol Cell Biol 13: 39-51.
7. Resh MD (2004) Membrane targeting of lipid modified signal transduction proteins. Subcell Biochem 37: 217-232.
8. Resh MD (2006) Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol 2: 504-509.
9. Resh MD (2006) Palmitoylation of ligands, receptors, and intracellular signaling molecules. Sci STKE 2006: re14.
10. Smotrys JE, Linder ME (2004) Palmitoylation of intracellular signaling proteins: regulation and function. Annu Rev Biochem 73: 559-587.
11. Baker TL, Zheng H, Walker J, Coloff JL, Buss JE (1999) Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic Ras. J Biol Chem 274: 19292-19300.
12. Chamberlain LH, Lemonidis K, Sanchez-Perez M, Werno MW, Gorleku OA, et al. (2013) Palmitoylation and the trafficking of peripheral membrane proteins. Nat Chem Biol 2: 584-590.
13. Fishburn GS, Herzenz L, Morales J, Bourne HR (1999) Gbetagamma and palmitoyl target newly synthesized Galphaz to the plasma membrane. J Biol Chem 274: 18793-18800.
14. Olino Y, Kashif A, Ogata R, Ishimota A, Yamazaki Y, et al. (2012) Analysis of substrate specificity of human DHHC protein acyltransferases using a yeast expression system. Mol Biol Cell 23: 4545-4551.
15. Rocks O, Peyker A, Kalims M, Verveer PJ, Koerner C, et al. (2005) An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 307: 1746-1752.
16. Draper JM, Xiao Z, Smith CD (2007) Cellular palmitoylation and trafficking of lipidated peptides. J Lipid Res 48: 1873-1884.
17. Rocks O, Gerauer M, Vartak N, Koch S, Huang ZP, et al. (2010) The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell 141: 470-481.
18. Sugimoto H, Hayashi H, Yamashita S (1996) Purification, cDNA cloning, and regulation of hyophospholipase from rat liver. J Biol Chem 271: 7055-7071.
19. Tomatis VM, Trenchi A, Gomez GA, Danioth JL (2010) Acyl-protein thioesterase 2 catalyzes the deacylation of peripheral membrane-associated GAP-43. PLoS One 5: e15045.
20. Toyoda T, Sugimoto H, Yamashita S (1999) Sequence, expression in Escherichia coli, and characterization of hyophospholipase II. Biochim Biophys Acta 1437: 102-193.
21. Dietzen DJ, Hastings WR, Lublin DM (1995) Carvedilol is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of carvedilol to caveolae. J Biol Chem 270: 6838-6842.
22. Tian L, McClefferty H, Knaus HG, Ruth P, Shipston MJ (2012) Distinct acyl protein transferase and thioesterase controlled surface expression of calcium-activated potassium channels. J Biol Chem 287: 14718-14725.
23. Duncan JA, Gilman AG (2002) Characterization of Saccharomyces cerevisiae acyl-protein thioesterase 1, the enzyme responsible for G protein alpha subunit deacylation in vivo. J Biol Chem 277: 31740-31752.
24. Draper JM, Smith CD (2009) Palmitoyl acyltransferase assays and inhibitors (Review). Mol Membr Biol 26: 5-13.
25. Resh MD (2006) Use of analogs and inhibitors to study the functional significance of protein palmitoylation. Methods 40: 191-197.
Inhibition of Protein Deacylation by 2-BP

36. Webb Y, Hermida-Matsumoto L, Resh MD (2000) Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids. J Biol Chem 275: 261–270.

37. Fukata M, Fukata Y, Nishikawa H, Nisoli RA, Bredt DS (2004) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

38. Jäkel W, Bredt DS, Nicoll RA, Nishikawa H, Fukata Y, et al. (2005) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

39. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

40. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

41. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

42. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

43. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

44. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

45. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

46. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

47. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

48. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

49. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

50. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

51. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

52. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

53. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

54. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.

55. Uchida Y, Nishikawa H, Fukata Y, Bredt DS, Nicoll RA (2006) Identification of PSD-95 palmitoylating enzymes. Neuron 44: 987–996.